Glimepiride

Glimepiride
Clinical data
Trade names	Amaryl, others
AHFS/Drugs.com	Monograph
MedlinePlus	a696016
License data	US DailyMed: Glimepiride;
Pregnancy; category	AU: C;
Routes of; administration	By mouth
ATC code	A10BB12 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); US: ℞-only; In general: ℞ (Prescription only);
Pharmacokinetic data
Bioavailability	100%
Protein binding	>99.5%
Metabolism	Complete Liver (1st stage through CYP2C9)
Onset of action	2–3 hours
Elimination half-life	5–8 hours
Duration of action	24 hours
Excretion	Urine (~60%), feces (~40%)
Identifiers
	IUPAC name 3-Ethyl-4-methyl-N-[2-(4-{[(trans-4-methylcyclohexyl)carbamoyl]sulfamoyl}phenyl)ethyl]-2-oxo-2,5-dihydro-1H-pyrrole-1-carboxamide;
CAS Number	93479-97-1 ;
PubChem CID	3476;
IUPHAR/BPS	6820;
DrugBank	DB00222 ;
ChemSpider	16740595 ;
UNII	6KY687524K;
KEGG	D00593 ;
ChEBI	CHEBI:5383 ;
ChEMBL	ChEMBL1481 ;
CompTox Dashboard (EPA)	DTXSID5040675 ;
ECHA InfoCard	100.170.771
Chemical and physical data
Formula	C24H34N4O5S
Molar mass	490.62 g·mol−1
3D model (JSmol)	Interactive image;
Melting point	207 °C (405 °F)
	SMILES O=C3C(/CC)=C(/C)CN3C(=O)NCCc1ccc(cc1)S(=O)(=O)NC(=O)N[C@H]2CC[C@H](C)CC2;
	InChI InChI=1S/C24H34N4O5S/c1-4-21-17(3)15-28(22(21)29)24(31)25-14-13-18-7-11-20(12-8-18)34(32,33)27-23(30)26-19-9-5-16(2)6-10-19/h7-8,11-12,16,19H,4-6,9-10,13-15H2,1-3H3,(H,25,31)(H2,26,27,30)/t16-,19- ; Key:WIGIZIANZCJQQY-RUCARUNLSA-N ;
	(what is this?) (verify)

Glimepiride is an antidiabetic medication within the sulfonylurea class, primarily prescribed for the management of type 2 diabetes. It is regarded as a second-line option compared to metformin, due to metformin's well-established safety and efficacy. Use of glimepiride is recommended in conjunction with lifestyle modifications such as diet and exercise. It is taken by mouth, reaching a peak effect within three hours and lasting for about a day.

Common side effects include headache, nausea, and dizziness. Serious side effects may include low blood sugar. Use during pregnancy and breastfeeding is not recommended. It works predominantly by increasing the amount of insulin released from the pancreas. It is classified as a second-generation sulfonylurea.

Glimepiride was patented in 1979 and approved for medical use in 1995. It is available as a generic medication. In 2021, it was the 74th most commonly prescribed medication in the United States, with more than 8 million prescriptions.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.